drugset / Trial / NCT00121017

A Study Exploring an Induction-Maintenance Kaletra-Based Therapy Versus a Sustiva-Based Regimen in Previously Non-Treated, HIV-1/HCV Co-Infected Subjects

NCT00121017

Phase 2 Withdrawn 200 enrolled Abbott
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether a simplified lopinavir/ritonavir-based therapy will continue to keep the viral load at very low levels after initial treatment with a combination of Kaletra (lopinavir/ritonavir) plus tenofovir and emtricitabine.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Efavirenz Other / unclassified
Subject Lopinavir Other / unclassified
Subject Ritonavir Other / unclassified
Subject Tenofovir disoproxil fumarate Small molecule
Subject emtricitabine Other / unclassified